| Stephanie M Heflin, RN, ANP-C | |
|
10497 Town And Country Way, Suite 360, Houston, TX 77024-1143 | |
| (713) 341-2100 | |
| (713) 932-7072 |
| Full Name | Stephanie M Heflin |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Adult Health |
| Location | 10497 Town And Country Way, Houston, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104136316 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207QA0505X | Family Medicine - Adult Medicine | 249415 (Texas) | Secondary |
| 363LA2200X | Nurse Practitioner - Adult Health | 249415 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie M Heflin, RN, ANP-C 10497 Town And Country Way, Suite 360, Houston, TX 77024-1143 Ph: (713) 341-2100 | Stephanie M Heflin, RN, ANP-C 10497 Town And Country Way, Suite 360, Houston, TX 77024-1143 Ph: (713) 341-2100 |
News Archive
The Australian Vaccination Network is involved in controversy yet again. The Bangalow-based anti-vaccination group has been given a timeline of 28 days to answer to claims that it breached charitable fundraising legislation on several occasions. It was only last month that the Health Care Complaints Commission had accused AVN of spreading misleading information about the dangers of immunization through its website.
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.
Researchers from IBM and the Institute of Bioengineering and Nanotechnology revealed today an antimicrobial hydrogel that can break through diseased biofilms and completely eradicate drug-resistant bacteria upon contact.
Since COVID-19 began its menacing march across Wuhan, China, in December 2019, and then across the world, the SARS-CoV-2 virus has taken a "whatever works" strategy to ensure its replication and spread.
› Verified 7 days ago